Staff Scientist

INVESTOR ALERT: Pomerantz law Firm reminds investors with losses on their investment in GRAIL, Inc. of class action lawsuit and upcoming deadlines - GRAL. NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) - Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. ("Grail" or the "Company") (NASDAQ: GRAL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Grail and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until August 4, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Grail securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." On this news, Grail's stock price fell more than 50%, damaging investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

GRAIL to present new data on multi-cancer early detection test. Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants. GRAIL will present additional data from the NHS-Galleri trial and the PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will further evaluate the Galleri multi-cancer early detection (MCED) test during the event held May 29 to June 2, 2026, in Chicago. The NHS-Galleri trial presentation will expand on topline results announced in February 2026. As a randomized controlled study of an MCED test, it was designed to demonstrate population-level impact through the reduction of late-stage cancer diagnosis and increased cancer detection rates within the National Health Service (NHS) in England. The trial evaluated annual screening with the Galleri test in addition to standard of care screening over three years in more than 142,000 participants aged 50 to 77. The complete dataset from the PATHFINDER 2 study, which includes more than 32,000 evaluable participants, will also be presented. Conducted under a Food and Drug Administration (FDA)-approved investigational device exemption, PATHFINDER 2 is an MCED interventional study in North America focused on an intended-use population with no clinical suspicion of cancer. "These results from NHS-Galleri and PATHFINDER 2, two large, rigorous studies, underscore Galleri's strong performance, ability to shift detection of cancers earlier before metastatic disease, and strong safety profile," says Josh Ofman, president of GRAIL, in a release. "We look forward to sharing these findings, which strengthen the body of evidence supporting the clinical utility, performance, and safety of Galleri in intended-use populations and reflect GRAIL's extensive experience building a robust evidence base for multi-cancer early detection." Additional data will include a poster presentation on the implementation of the MCED test in private practice settings. This study examines adoption, performance, and repeat-testing patterns for the blood-based screening tool. The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. While the Galleri test is intended for clinical purposes, it has not been cleared or approved by the FDA. The test is currently recommended for adults with an elevated risk for cancer, such as those aged 50 or older, and is intended to be used in addition to routine cancer screening tests. Photo caption: Galleri test Photo credit: File/GRAIL Related Reading: